Polycystic Ovarian Syndrome (PCOS) is a common endocrine disorder where reproductive and metabolic pathways collide — ovarian dysfunction, hyperandrogenism, and insulin resistance form a triad that affects fertility, appearance, and long-term health. It’s not just “cysts” on the ovary; it’s a systemic syndrome with ripple effects across a woman's life.
🔄 Overview of PCOS
PCOS is characterized by irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. It affects up to 10–15% of reproductive-aged women depending on diagnostic criteria and carries metabolic risks including insulin resistance, dyslipidaemia and increased cardiovascular risk.
Core Features
- Diagnostic triad: Oligo/anovulation, hyperandrogenism, polycystic ovaries
- Endocrine milieu: Elevated androgens, LH:FSH imbalance
- Metabolic: Insulin resistance common
- Heterogeneous: Multiple phenotypes exist
Epidemiology
- Prevalence: ~6–15% (varies by criteria)
- Age: Manifests in adolescence/early adulthood
- Risk Factors: Family history, obesity
- Long-term: Increased risk of T2DM and CVD
🧬 Pathophysiology: A Web of Hormones and Metabolism
PCOS arises from interactions between ovarian dysfunction, adrenal contributions, and systemic insulin resistance. Insulin amplifies ovarian androgen production and reduces hepatic sex hormone–binding globulin (SHBG), increasing free testosterone. Genetic predisposition and environmental triggers (obesity, lifestyle) shape the phenotype.
Insulin Resistance
- Peripheral insulin resistance common in muscle/adipose
- Hyperinsulinaemia stimulates ovarian theca cells → androgens
- Exacerbates metabolic and reproductive dysfunction
Ovarian & Gonadotroph Axis
- Increased LH pulse frequency → ovarian androgen production
- Altered folliculogenesis → arrested antral follicles ("polycystic" appearance)
- Relative FSH deficiency impairs dominant follicle selection
Androgen Effects
- Hirsutism, acne, androgenic alopecia
- Negative feedback alterations on HPO axis
- Impact on endometrium (unopposed estrogen if anovulatory)
💧 Clinical Features: Reproductive and Metabolic Clues
Presentation varies — from teenage irregular menses and severe acne to adult infertility or metabolic syndrome. Clinical suspicion should be high when multiple features coexist.
Common Manifestations
Reproductive
- Oligomenorrhea or amenorrhea
- Infertility due to anovulation
- Polycystic ovarian morphology on ultrasound
Androgenic & Metabolic
- Hirsutism (terminal hair in androgenic distribution)
- Acne, oily skin, hair thinning
- Obesity, insulin resistance, dyslipidaemia
🔬 Diagnosis: Clinical Criteria & Workup
Diagnosis is clinical using accepted criteria (Rotterdam criteria commonly used): need two of three — oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovaries on ultrasound — after excluding other causes (thyroid disease, hyperprolactinaemia, non-classic CAH, androgen-secreting tumours).
Key Diagnostic Tools
| Test | Purpose | Findings |
|---|---|---|
| Clinical history & exam | Assess menstrual pattern, hirsutism | Oligomenorrhea, hirsutism score (e.g., Ferriman–Gallwey) |
| Serum androgens | Biochemical hyperandrogenism | Elevated total/free testosterone, DHEA-S to rule adrenal source |
| Pelvic ultrasound | Polycystic ovarian morphology | ≥20 follicles per ovary (modern thresholds) or ovarian volume >10 mL |
| Metabolic screening | Assess cardiometabolic risk | Fasting glucose, OGTT, lipids, BP, BMI |
🎯 Management & Treatment
Management is individualized depending on goals: symptom control (hirsutism, acne), menstrual regulation, fertility, and metabolic risk reduction. Lifestyle changes form the foundation for most patients.
First-line & Lifestyle
- Weight loss (5–10%) improves ovulation and insulin sensitivity
- Dietary changes, exercise, behavioural support
- Smoking cessation and cardiometabolic risk control
Pharmacologic Options
- Combined oral contraceptives: Regulate menses, reduce androgens
- Metformin: Improves insulin sensitivity, aids weight and ovulation
- Anti-androgens (e.g., spironolactone): For hirsutism (use with contraception)
- Clomiphene citrate / Letrozole: Ovulation induction (letrozole preferred for fertility)
Procedural & Surgical
- Ovarian drilling (laparoscopic) — reserved for selected clomiphene-resistant cases
- Assisted reproductive technologies for infertility (IVF)
Long-term Care
- Regular metabolic screening (OGTT, lipids, BP)
- Endometrial protection if prolonged anovulation (cyclic progestins or OCPs)
- Address psychosocial effects — mood, body image
⚠️ Complications & Prognosis
PCOS carries reproductive and metabolic complications across the lifespan. Early identification and long-term follow-up mitigate risk.
- Reproductive: Infertility, pregnancy complications (gestational diabetes, preeclampsia)
- Metabolic: Type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease
- Cardiovascular: Increased risk factors — long-term CVD risk debated but concerning
- Endometrial: Hyperplasia and carcinoma from chronic anovulation
- Psychological: Depression, anxiety, reduced quality of life
🧠 Key Takeaways
- PCOS is a common hormonal disorder combining ovulatory dysfunction, hyperandrogenism, and polycystic ovaries.
- Insulin resistance is central to many cases and amplifies ovarian androgen production.
- Diagnosis requires careful exclusion of mimics and is based on accepted clinical criteria (e.g., Rotterdam).
- Management is individualized: lifestyle first, then targeted pharmacotherapy for symptoms or fertility.
- Long-term follow-up for metabolic and endometrial risks is essential.
🧭 Conclusion
Polycystic Ovarian Syndrome is more than "cysts" — it is a multisystem syndrome where hormonal and metabolic disturbances shape reproductive health and long-term disease risk. With a combination of lifestyle interventions, targeted medications, and careful monitoring, many women with PCOS can achieve symptom control, fertility goals, and better metabolic health. Understanding its biology empowers clinicians and patients to turn a complex puzzle into manageable pieces.
PCOS is a life-course condition: the earlier we detect and treat metabolic and reproductive components, the better the outcomes across reproductive years and beyond.